Academic Journal
Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss
| العنوان: | Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss |
|---|---|
| المؤلفون: | Jacob, S., Rabbia, M., Meier, M. K., Hauptman, J. |
| المصدر: | Diabetes, Obesity and Metabolism ; volume 11, issue 4, page 361-371 ; ISSN 1462-8902 1463-1326 |
| بيانات النشر: | Wiley |
| سنة النشر: | 2009 |
| المجموعة: | Wiley Online Library (Open Access Articles via Crossref) |
| الوصف: | Background: Both obesity and type 2 diabetes are associated with increased morbidity and mortality. Published data suggest that orlistat 120 mg, a lipase inhibitor used to treat obesity, may improve glycaemic parameters through weight loss–independent effects. Aim: To investigate the effect of orlistat 120 mg on weight loss, and assess whether changes in glycaemic parameters [fasting plasma glucose (FPG) and haemoglobin A 1c (HbA 1c )] are independent of weight loss. Methods: This retrospective analysis of pooled data from seven multicentre, double‐blind, placebo‐controlled studies involved overweight or obese patients with type 2 diabetes (aged 18–70 years). Patients were required to have a body mass index of 27–43 kg/m 2 , HbA 1c of 6.5 to <13%, and stable weight for ≥3 months. Subjects received orlistat 120 mg tid or placebo for 6 or 12 months. Results: A total of 2550 overweight or obese patients with type 2 diabetes were enrolled and randomized to treatment with orlistat 120 mg tid (n = 1279) or placebo (n = 1271). For the whole population, patients treated with orlistat 120 mg had significantly greater mean decreases in FPG compared with placebo‐treated patients (−1.39 mmol/l vs. −0.47 mmol/l; p < 0.0001). In addition, orlistat 120 mg provided significantly larger mean decreases in HbA 1c compared with placebo (−0.74% vs. −0.31%; p < 0.0001). For patients with minimal weight loss (≤1% of baseline body weight), orlistat 120 mg still provided a significantly greater decrease in the least squares mean value for both FPG (−0.83 mmol/l vs. ±0.02 mmol/l; p = 0.0052) and HbA 1c −0.29% vs. ±0.14%; p = 0.0008). This suggested that the improvement of glycaemic control with orlistat 120 mg was independent of weight loss. Using linear regression analysis, improvement in glycaemic control (FPG and HbA 1c ) with orlistat 120 mg was less strongly correlated with weight loss than for placebo. Conclusion: Orlistat 120 mg appears to improve glycaemic control more than would be predicted by weight loss alone in ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1111/j.1463-1326.2008.00970.x |
| DOI: | 10.1111/j.1463-1326.2008.00970.x/fullpdf |
| الاتاحة: | http://dx.doi.org/10.1111/j.1463-1326.2008.00970.x https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1463-1326.2008.00970.x http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1463-1326.2008.00970.x/fullpdf |
| Rights: | http://onlinelibrary.wiley.com/termsAndConditions#vor |
| رقم الانضمام: | edsbas.16E80398 |
| قاعدة البيانات: | BASE |
كن أول من يترك تعليقا!